Erythropoietin levels in patients with multiple sclerosis complicated with anemia.
- Author:
De-he WANG
1
;
Yong-mei LI
;
Tong-hua WU
;
Jing LI
;
Dan-hui SU
;
Nuo-wei XIANG
;
Zhi Xin-yue XIANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Anemia; blood; etiology; Case-Control Studies; Erythropoietin; blood; Female; Humans; Male; Middle Aged; Multiple Sclerosis; blood; complications; Young Adult
- From: Acta Academiae Medicinae Sinicae 2013;35(1):84-87
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the potential decrease of serum erythropoietin (EPO) level in patients with multiple sclerosis (MS) complicated with anemia.
METHODSThe serum EPO levels were detected in the patients with MS complicated with anemia (MS group, n=31), patients with iron deficiency anemia (IDA group, n=33), and healthy subjects (normal control group, n=80) by enzyme-linked immunosorbent assay (ELISA). Blood routine test, reticulocyte count, hemoglobin, and indexes of liver and kidney function were also detected.
RESULTSThe serum EPO level in MS group was significantly lower than those in IDA group [(101.3±17.6)U/L vs.(166.1±8.7)U/L, P<0.01]. Moreover, the serum EPO level decreased as the severity of anemia in the MS group increased: it was (95.7±9.6), (101.7±8.1), and (123.7±9.3) U/L in patients with mild, moderate, and severe anemia, respectively (P<0.05). Other indicators including blood routine findings, reticulocyte count, hemoglobin, and liver and kidney function parameters showed no significant difference between the MS group and the IDA group (P>0.05).
CONCLUSIONSThe serum EPO level decreases in patients with multiple sclerosis complicated with anemia, and the decreasing levels are related with the severity of anemia. Thus EPO therapy may be beneficial for these patients.
